Beijing Beilu Pharmaceutical (300016) — Tangible Net Worth Ratio
Beijing Beilu Pharmaceutical (300016) has a Tangible Net Worth Ratio of 93.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥152.07 Million) from net assets (CN¥2.37 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300016 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Beijing Beilu Pharmaceutical Tangible Net Worth Ratio (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Tangible Net Worth Ratio has changed across 20 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 93.6%, reflecting net assets of CN¥2.37 Billion with intangible assets of CN¥152.07 Million CNY. See Beijing Beilu Pharmaceutical defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Beijing Beilu Pharmaceutical (2005–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Beijing Beilu Pharmaceutical market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.2% | CN¥1.83 Billion | CN¥160.82 Million | CN¥2.98 Billion | ▼ -1.6 pp |
| 2023 | 92.8% | CN¥1.79 Billion | CN¥128.39 Million | CN¥2.82 Billion | ▲ +0.5 pp |
| 2022 | 92.3% | CN¥1.92 Billion | CN¥147.26 Million | CN¥2.82 Billion | ▲ +0.0 pp |
| 2021 | 92.3% | CN¥2.08 Billion | CN¥160.39 Million | CN¥2.90 Billion | ▲ +1.1 pp |
| 2020 | 91.2% | CN¥1.89 Billion | CN¥167.07 Million | CN¥2.85 Billion | ▼ -4.9 pp |
| 2019 | 96.0% | CN¥1.45 Billion | CN¥57.71 Million | CN¥1.62 Billion | ▲ +0.1 pp |
| 2018 | 95.9% | CN¥1.21 Billion | CN¥49.69 Million | CN¥1.29 Billion | ▲ +0.9 pp |
| 2017 | 95.0% | CN¥1.07 Billion | CN¥53.26 Million | CN¥1.14 Billion | ▼ -0.2 pp |
| 2016 | 95.2% | CN¥901.69 Million | CN¥43.47 Million | CN¥956.09 Million | ▲ +0.7 pp |
| 2015 | 94.4% | CN¥932.63 Million | CN¥51.83 Million | CN¥1.05 Billion | ▲ +0.8 pp |
| 2014 | 93.7% | CN¥666.33 Million | CN¥42.07 Million | CN¥907.00 Million | ▼ -3.4 pp |
| 2013 | 97.1% | CN¥559.38 Million | CN¥16.05 Million | CN¥620.54 Million | ▼ -0.8 pp |
| 2012 | 98.0% | CN¥523.96 Million | CN¥10.70 Million | CN¥583.60 Million | ▼ -1.1 pp |
| 2011 | 99.1% | CN¥491.47 Million | CN¥4.54 Million | CN¥524.66 Million | ▲ +0.1 pp |
| 2010 | 99.0% | CN¥467.62 Million | CN¥4.60 Million | CN¥475.11 Million | ▼ -0.1 pp |
| 2009 | 99.1% | CN¥433.71 Million | CN¥3.90 Million | CN¥451.31 Million | ▲ +2.4 pp |
| 2008 | 96.7% | CN¥133.23 Million | CN¥4.40 Million | CN¥159.75 Million | ▲ +2.6 pp |
| 2007 | 94.0% | CN¥90.33 Million | CN¥5.38 Million | CN¥141.69 Million | ▼ -0.4 pp |
| 2006 | 94.5% | CN¥71.59 Million | CN¥3.95 Million | CN¥125.69 Million | ▲ +1.8 pp |
| 2005 | 92.7% | CN¥64.71 Million | CN¥4.72 Million | CN¥107.46 Million | — |